June 10, 2020 / 12:18 PM / 2 months ago

BRIEF-Qualigen Signs Exclusive License Agreement With University Of Louisville, Plans To Develop AS1411 For Treatment Of COVID-19

June 10 (Reuters) - Qualigen Therapeutics Inc:

* QUALIGEN THERAPEUTICS SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF LOUISVILLE, PLANS TO DEVELOP AS1411 FOR TREATMENT OF COVID-19

* QUALIGEN - HAS HELD AN EXCLUSIVE LICENSE TO AS1411 FOR ALL FIELDS OF USE SINCE 2018

* QUALIGEN - AGREED TO PAY UOFL ROYALTIES IN LOW-TO-MID-SINGLE-DIGIT PERCENTAGES ON AS1411 ANTI-COVID-19 PRODUCT SALES USING UOFL’S TECHNOLOGY, PATENTS

* QUALIGEN - UNDERTOOK TO ENTER SPONSORED RESEARCH AGREEMENT WITH UOFL FOR FURTHER IN VITRO AND PRECLINICAL ANIMAL STUDIES WITH AS1411 AGAINST COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below